Screening for extranodal extension in HPV-associated oropharyngeal carcinoma: evaluation of a CT-based deep learning algorithm in patient data from a multicentre, randomised de-escalation trial
Benjamin H. Kann(Brigham and Women's Hospital), Robert L. Ferris(University of Pittsburgh), Amy F. Juliano(Massachusetts Eye and Ear Infirmary), Barbara Burtness(Yale University), Jonathan D. Schoenfeld(Brigham and Women's Hospital), Sanjay Aneja(Yale University), Yael Flamand(Dana-Farber Cancer Institute), Dennis Bontempi(Maastricht University Medical Centre), Jirapat Likitlersuang(Brigham and Women's Hospital), Rathan M. Subramaniam(Dunedin Public Hospital), Ravindra Uppaluri(Brigham and Women's Hospital), Richard L. Bakst(Icahn School of Medicine at Mount Sinai), Roy B. Tishler(Dana-Farber Cancer Institute), Danielle N. Margalit(Harvard University), Hillary R. Kelly(Massachusetts Eye and Ear Infirmary), Robert I. Haddad(Georgetown University), Zezhong Ye(Brigham and Women's Hospital), Jeffrey P. Guenette(Brigham and Women's Hospital), Joaquín J. García(Mayo Clinic in Arizona), Hugo J.W.L. Aerts(Harvard University)
Cited by 74
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
Recent Advances in Head and Neck Cancer
|New England Journal of Medicine|2008|926